Health Economics & Outcomes Research, Product Director, Oncology
Boehringer Ingelheim Pharmaceuticals, Inc.
Elizabeth ("Liz") Stanley was the Health Economics and Outcomes Research (HEOR) Product Director for the Oncology portfolio at Boehringer Ingelheim at the time of this study. In this role, she significantly contributed to the success of Boehringer’s Oncology portfolio through her HEOR strategy and value evidence generation. She is now the Global HEOR Lead for Retinal Health at Boehringer, responsible for the global HEOR value demonstration strategy for Boehringer's Retinal Health portfolio.
Liz's diverse background spans biopharmaceutical companies, consulting, and academia, demonstrating broad expertise in health economics, policy, quality, outcomes research, and health services research across various therapeutic areas and diseases. Before joining Boehringer in 2015, where she has held various roles within the US Value & Access organization, Liz worked at the Deloitte Center for Health Solutions and Novartis, where she conducted rigorous health services/policy research and generated HEOR evidence to support strategic imperatives and product lifecycle management across various therapeutic areas.
Liz is currently pursuing her Ph.D. in Translational Health Sciences at The George Washington University. She completed a post-graduate fellowship in HEOR through Rutgers University and Novartis, and holds a Master of Public Health (M.P.H.) in Health Policy and Epidemiology from Emory University. Her extensive experience and academic achievements make her a leading figure in her field and a valuable asset to Boehringer.
